Pharmacological inhibition of inflammatory pathways for the prevention of preterm birth

Journal of Reproductive Immunology

Volumn 88, Issue 2, 2011, Pages 176-184

  Keelan, J A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Amniotic fluid; Chorioamnionitis; Cytokines; Inflammation; Microbial infection; NF B; Preterm birth

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ETANERCEPT; HISTONE DEACETYLASE; HYDROXYPROGESTERONE CAPROATE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; ROLIPRAM; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR; TPCA 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHORION; DRUG EFFICACY; DRUG SAFETY; FEMALE GENITAL TRACT INFLAMMATION; GENE ACTIVATION; GENE EXPRESSION; HUMAN; INFLAMMATION; INTRAUTERINE INFECTION; NONHUMAN; OXIDATIVE STRESS; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; CHORIOAMNIONITIS; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; PERINATAL CARE; PREGNANCY; PREMATURE BIRTH; UTERUS;

EID: 79952709239     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.11.003     Document Type: Article

References (114)

1. Aaltonen R., et al. Local inflammatory response in choriodecidua induced by Ureaplasma urealyticum. BJOG 2007, 114:1432-1435.
2. Abrahams V.M. Pattern recognition at the maternal-fetal interface. Immunol. Invest. 2008, 37:427-447.
3. Abrahams V.M., et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J. Immunol. 2004, 173:4286-4296.
4. Adams Waldorf K.M., et al. Pretreatment with toll-like receptor 4 antagonist inhibits lipopolysaccharide-induced preterm uterine contractility, cytokines, and prostaglandins in rhesus monkeys. Reprod. Sci. 2008, 15:121-127.
5. Annells M.F., et al. Polymorphisms in immunoregulatory genes and the risk of histologic chorioamnionitis in Caucasoid women: a case control study. BMC Pregnancy Childbirth 2005, 5:4.
6. Brar H., Einarson A. Effects and treatment of inflammatory bowel disease during pregnancy. Can. Fam. Physician 2008, 54:981-983.
7. Buhimschi I.A., et al. Protective effect of N-acetylcysteine against fetal death and preterm labor induced by maternal inflammation. Am. J. Obstet. Gynecol. 2003, 188:203-208.
8. Cardenas I., et al. Placental viral infection sensitizes to endotoxin-induced pre-term labor: a double hit hypothesis. Am. J. Reprod. Immunol. 2010.
9. Carter J.D., et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol. 2008.
10. Cohen S.B., et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009, 60:335-344.
11. Connell W., Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 1999, 21:311-323.
12. Damjanov N., et al. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009, 60:1232-1241.
13. De Silva D., et al. Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors. Br. J. Pharmacol. 2010, 160:1808-1822.
14. Digiulio D.B., et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS ONE 2008, 3:e3056.
15. Dofferhoff A.S., et al. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand. J. Infect. Dis. 1991, 23:745-754.
16. Dollner H., et al. Histologic chorioamnionitis and umbilical serum levels of pro-inflammatory cytokines and cytokine inhibitors. BJOG 2002, 109:534-539.
17. Dulay A.T., et al. Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J. Immunol. 2009, 182:7244-7253.
18. Elovitz M.A. Anti-inflammatory interventions in pregnancy: now and the future. Semin. Fetal Neonatal Med. 2006, 11:327-332.
19. Filipovich Y., et al. The adaptor protein MyD88 is essential for E coli-induced preterm delivery in mice. Am. J. Obstet. Gynecol. 2009, 200:93.e1-93.e8.
20. Franova S., et al. Utero-relaxant effect of PDE4-selective inhibitor alone and in simultaneous administration with beta2-mimetic on oxytocin-induced contractions in pregnant myometrium. J. Obstet. Gynaecol. Res. 2009, 35:20-25.
21. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br. J. Pharmacol. 2008, 155:288-290.
22. Goldenberg R.L., et al. Epidemiology and causes of preterm birth. Lancet 2008, 371:75-84.
23. Gomez R., et al. The role of infection in preterm delivery. Preterm Labor 1997, Churchill Livingstone, New York, pp. 85-126. M.G. Elder (Ed.).
24. Gomez R., et al. Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J. Matern. Fetal Neonatal Med. 2007, 20:167-173.
25. Gonzalez J., et al. TLRs, the lower genital tract and pregnancy. Am. J. Obstet. Gynecol. 2006, 195:S9.
26. Grigsby P.L., et al. Choriodecidual inflammation: a harbinger of the preterm labor syndrome. Reprod. Sci. 2010, 17:85-94.
27. Han Y.W., et al. Uncultivated bacteria as etiologic agents of intra-amniotic inflammation leading to preterm birth. J. Clin. Microbiol. 2009, 47:38-47.
28. Holmgren C., et al. Evaluation of the use of anti-TNFalpha in an LPS-induced murine model. J. Reprod. Immunol. 2008, 78:134-139.
29. Holmlund U., et al. Expression and regulation of the pattern recognition receptors Toll-like receptor-2 and Toll-like receptor-4 in the human placenta. Immunology 2002, 107:145-151.
30. Holzheimer R.G. Antibiotic induced endotoxin release and clinical sepsis: a review. J. Chemother. 2001, 13(Spec No 1):159-172.
31. Hou Y., et al. Analysis of the IKKbeta/NF-kappaB signaling pathway during embryonic angiogenesis. Dev. Dyn. 2008, 237:2926-2935.
32. Hutzal C.E., et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am. J. Obstet. Gynecol. 2008, 199:620.e1-620.e8.
33. Imai Y., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008, 133:235-249.
34. Ishaq S., Green J.R. Tolerability of aminosalicylates in inflammatory bowel disease. BioDrugs 2001, 15:339-349.
35. Jacobsson B., et al. Quantification of Ureaplasma urealyticum DNA in the amniotic fluid from patients in PTL and pPROM and its relation to inflammatory cytokine levels. Acta Obstet. Gynecol. Scand. 2009, 88:63-70.
36. Jones H.E., et al. Differing prevalence and diversity of bacterial species in fetal membranes from very preterm and term labor. PLoS ONE 2009, 4:e8205.
37. Jung H.S., et al. Differential activation of mitogen activated protein kinases and nuclear factor-kappaB in lipopolysaccharide-treated term and preterm amnion cells. Virchows Arch. 2005, 447:45-52.
38. Kaindl A.M., et al. Molecular mechanisms involved in injury to the preterm brain. J. Child Neurol. 2009, 24:1112-1118.
39. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect. Biol. 2009, 1:a000141.
40. Karin M., Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol. Rev. 2009, 228:225-240.
41. Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 2007, 13:460-469.
42. Keelan J.A., et al. Cytokines, prostaglandins and parturition-a review. Placenta 2003, 24:S33-46.
43. Keelan J.A., et al. Prevention of inflammatory activation of human gestational membranes in an ex vivo model using a pharmacological NF-kappaB inhibitor. J. Immunol. 2009, 183:5270-5278.
44. Knox C.L., et al. The severity of chorioamnionitis in pregnant sheep is associated with in vivo variation of the surface-exposed multiple-banded antigen/gene of Ureaplasma parvum. Biol. Reprod. 2010, 83:415-426.
45. Koga K., Mor G. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am. J. Reprod. Immunol. 2010, 63:587-600.
46. Kramer B.W., et al. Endotoxin-induced chorioamnionitis modulates innate immunity of monocytes in preterm sheep. Am. J. Respir. Crit. Care Med. 2005, 171:73-77.
47. Krediet T.G., et al. Toll-like receptor 2 polymorphism is associated with preterm birth. Pediatr. Res. 2007, 62:474-476.
48. Kumagai Y., et al. Pathogen recognition by innate receptors. J. Infect. Chemother. 2008, 14:86-92.
49. Kumar S., et al. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003, 2:717-726.
50. Lamarca H.L., et al. Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Hum. Reprod. 2008, 23:1733-1741.
51. Lamont R.F., Jaggat A.N. Emerging drug therapies for preventing spontaneous preterm labor and preterm birth. Expert Opin. Investig. Drugs 2007, 16:337-345.
52. Lappas M., et al. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J. Clin. Endocrinol. Metab. 2003, 88:1723-1729.
53. Lappas M., et al. Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J. Endocrinol. 2007, 193:269-277.
54. Lappas M., et al. Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues. Placenta 2007, 28:936-945.
55. Lappas M., et al. Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 2005, 146:1491-1497.
56. Lee S.E., et al. The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. Am. J. Obstet. Gynecol. 2007, 197:294.e1-294.e6.
57. Li Z.W., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 1999, 189:1839-1845.
58. Lindstrom T.M., Bennett P.R. The role of nuclear factor kappa B in human labour. Reproduction 2005, 130:569-581.
59. Lu Y.C., et al. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
60. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003, 21:3352-3357.
61. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007, 14:10-22.
62. Mehats C., et al. PDE4 as a target in preterm labour. BMC Pregnancy Childbirth 2007, 7(Suppl 1):S12.
63. Miller J.L., et al. Perinatal outcomes after second trimester detection of amniotic fluid viral genome in asymptomatic patients. J. Perinat. Med. 2009, 37:140-143.
64. Mollen K.P., et al. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006, 26:430-437.
65. Moss T.J., et al. Chorioamnionitis induced by subchorionic endotoxin infusion in sheep. Am. J. Obstet. Gynecol. 2003, 189:1771-1776.
66. Moutsopoulos N.M., Madianos P.N. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann. N. Y. Acad. Sci. 2006, 1088:251-264.
67. Newnham J.P., et al. The effects of intra-amniotic injection of periodontopathic lipopolysaccharides in sheep. Am. J. Obstet. Gynecol. 2005, 193:313-321.
68. Norgard B., et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol. Ther. 2001, 15:483-486.
69. Norgard B., et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am. J. Gastroenterol. 2007, 102:1406-1413.
70. Norman J.E., et al. Inflammatory pathways in the mechanism of parturition. BMC Pregnancy Childbirth 2007, 7(Suppl. 1):S7.
71. Oger S., et al. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. J. Immunol. 2005, 174:8082-8089.
72. Oh K.J., et al. Detection of ureaplasmas by the polymerase chain reaction in the amniotic fluid of patients with cervical insufficiency. J. Perinat. Med. 2010, 38:261-268.
73. Oldenhof A.D., et al. Mitogen-activated protein kinases mediate stretch-induced c-fos mRNA expression in myometrial smooth muscle cells. Am. J. Physiol. Cell Physiol. 2002, 283:C1530-C1539.
74. Onderdonk A.B., et al. Detection of bacteria in placental tissues obtained from extremely low gestational age neonates. Am. J. Obstet. Gynecol. 2008, 198:110.e1-110.e7.
75. Paintlia M.K., et al. Attenuation of lipopolysaccharide induced inflammatory response and phospholipids metabolism at the feto-maternal interface by N-acetyl-cysteine. Pediatr. Res. 2008, 64:334-339.
76. Pararas M.V., et al. Preterm birth due to maternal infection: causative pathogens and modes of prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2006, 25:562-569.
77. Park C.W., et al. The involvement of human amnion in histologic chorioamnionitis is an indicator that a fetal and an intra-Amniotic inflammatory response is more likely and severe: clinical implications. Placenta 2009, 30:56-61.
78. Park C.W., et al. The frequency and clinical significance of intra-uterine infection and inflammation in patients with placenta previa and preterm labor and intact membranes. Placenta 2009, 30:613-618.
79. Plunkett J., Muglia L.J. Genetic contributions to preterm birth: implications from epidemiological and genetic association studies. Ann. Med. 2008, 40:167-195.
80. Rahimi R., et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod. Toxicol. 2008, 25:271-275.
81. Romero R., et al. The role of inflammation and infection in preterm birth. Semin. Reprod. Med. 2007, 25:21-39.
82. Romero R., et al. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr. Rev. 2007, 65:S194-S202.
83. Romero R., et al. A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am. J. Obstet. Gynecol. 2010, 203(4). 361.e1-361.e30.
84. Roux C.H., et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007, 46:695-698.
85. Sato A., et al. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Int. J. Oncol. 2006, 28:841-846.
86. Sato T.A., et al. Critical paracrine interactions between TNFalpha and IL-10 regulate lipopolysaccharide-stimulated human choriodecidual cytokine and prostaglandin E2 production. J. Immunol. 2003, 170:158-166.
87. Schmitz T., et al. PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation. J. Immunol. 2007, 178:1115-1121.
88. Seong H.S., et al. Lack of evidence for microorganisms in most women with clinical chorioamnionitis: a need to revisit the clinical and microbiologic criteria for one of the most important obstetrical complications. Am. J. Obstet. Gynecol. 2006, 195:S73.
89. Shahin A.Y., et al. Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis. Int. J. Gynaecol. Obstet. 2009, 104:44-48.
90. Shennan A.H., Chandiramani M. Antibiotics for spontaneous preterm birth. BMJ 2008, 337:a3015.
91. Shoji T., et al. Involvement of p38 MAP kinase in lipopolysaccharide-induced production of pro- and anti-inflammatory cytokines and prostaglandin E(2) in human choriodecidua. J. Reprod. Immunol. 2007, 75:82-90.
92. Simhan H.N., et al. Maternal and fetal Toll-like receptor 4 genotype and chorionic plate inflammatory lesions. Am. J. Obstet. Gynecol. 2008, 199:400.e1-400.e4.
93. Skaug B., et al. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 2009, 78:769-796.
94. Sooranna S.R., et al. The mitogen-activated protein kinase dependent expression of prostaglandin H synthase-2 and interleukin-8 messenger ribonucleic acid by myometrial cells: the differential effect of stretch and interleukin-1beta. J. Clin. Endocrinol. Metab. 2005, 90:3517-3527.
95. Spina D. PDE4 inhibitors: current status. Br. J. Pharmacol. 2008, 155:308-315.
96. Steel J.H., et al. Bacteria and inflammatory cells in fetal membranes do not always cause preterm labor. Pediatr. Res. 2005, 57:404-411.
97. Stewart C.R., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
98. Thomakos N., et al. Amniotic fluid interleukin-6 and tumor necrosis factor-alpha at mid-trimester genetic amniocentesis: relationship to intra-amniotic microbial invasion and preterm delivery. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010, 148:147-151.
99. Ugwumadu A., et al. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003, 361:983-988.
100. Ugwumadu A., et al. Oral clindamycin and histologic chorioamnionitis in women with abnormal vaginal flora. Obstet. Gynecol. 2006, 107:863-868.
101. Vaillancourt C., et al. Involvement of MAPK signalling in human villous trophoblast differentiation. Mini Rev. Med. Chem. 2009, 9:962-973.
102. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27:693-733.
103. Van Den Broek N.R., et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. PLoS Med. 2009, 6:e1000191.
104. Vasiliauskas E.A., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 2006, 4:1255-1258.
105. Villagra A., et al. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 2010, 29(2):157-173.
106. Vora S., et al. Nuclear factor-kappa B localization and function within intrauterine tissues from term and preterm labor and cultured fetal membranes. Reprod. Biol. Endocrinol. 2010, 8:8.
107. Weber C.K., et al. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000, 119:1209-1218.
108. West X.Z., et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010, 467:972-976.
109. Winger E.E., Reed J.L. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 2008, 60:8-16.
110. Winger E.E., et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am. J. Reprod. Immunol. 2009, 61:113-120.
111. Xu D.X., et al. Effect of N-acetylcysteine on lipopolysaccharide-induced intra-uterine fetal death and intra-uterine growth retardation in mice. Toxicol. Sci. 2005, 88:525-533.
112. Yan J., Hales B.F. p38 and c-Jun N-terminal kinase mitogen-activated protein kinase signaling pathways play distinct roles in the response of organogenesis-stage embryos to a teratogen. J. Pharmacol. Exp. Ther. 2008, 326:764-772.
113. Yan X., et al. Localization of nuclear factor-kappa B (NF kappa B) and inhibitory factor-kappa B (I kappa B) in human fetal membranes and decidua at term and preterm delivery. Placenta 2002, 23:288-293.
114. Zafarullah M., et al. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003, 60:6-20.